Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…Abstract Number: 0277 • ACR Convergence 2021
Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
Background/Purpose: A relationship between rheumatoid arthritis (RA) and the presence of abnormalities in left ventricular (LV) geometry such as eccentric remodeling has recently been determined,…Abstract Number: 0643 • ACR Convergence 2021
Tailored BP Connect Protocol with Implementation Support for Rheumatology Clinic Staff Exceeds Non-tailored Protocol at Improving Primary Care Referrals for Blood Pressure Follow-up
Background/Purpose: Many rheumatic diseases increase risk of cardiovascular disease, yet an important modifiable cardiovascular risk factor, high blood pressure (BP), often remains unaddressed during rheumatology…Abstract Number: 1245 • ACR Convergence 2021
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
Background/Purpose: In recent decades, the therapeutic arsenal in RA has dramatically expanded. Baricitinib (BARI) and Tofacitinib (TOFA) were the first JAK inhibitors (JAKi) to be…Abstract Number: 1898 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis
Background/Purpose: Acute calcium pyrophosphate (CPP) crystal arthritis, also known as pseudogout, causes an acute inflammatory arthritis that shares clinical similarities with gout. We investigated the…Abstract Number: 0278 • ACR Convergence 2021
Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of cardiovascular diseases and a strong association with abnormalities in the left ventricular (LV) geometry.…Abstract Number: 0644 • ACR Convergence 2021
Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems
Background/Purpose: To address high blood pressure (BP), target of two ACR quality measures and the leading modifiable risk factor for cardiovascular disease, we previously developed…Abstract Number: 1308 • ACR Convergence 2021
Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with cardiovascular abnormalities. The echocardiography is a non-invasive tool useful in the detection of cardiac…Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…Abstract Number: 0282 • ACR Convergence 2021
5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
Background/Purpose: Rheumatoid arthritis (RA) is associated with higher cardiovascular disease (CVD) risk due to the underlying inflammation.It is uncertain if the excess CV risk could…Abstract Number: 0645 • ACR Convergence 2021
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…Abstract Number: 1315 • ACR Convergence 2021
The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients
Background/Purpose: Systemic inflammation in psoriatic arthritis (PsA) patients accelerates the process of atherosclerosis; this increases the risk of presenting a major cardiovascular (CV) event than…Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…Abstract Number: 0283 • ACR Convergence 2021
Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
Background/Purpose: Cardiovascular (CV) disease is the leading cause of death in patients with rheumatoid arthritis (RA) and is estimated to be responsible for 29%-32% of…
- 1
- 2
- 3
- …
- 10
- Next Page »